BACKGROUND: To improve the therapy of advanced prostate cancer (CaP), it is critical to develop animal models that mimic CaP bone metastases. Unlike the human disease, CaP xenograft models rarely metastasize spontaneously to bone from the orthotopic site of primary tumor growth. METHODS: Single-cell suspensions of LNCaP, PC-3, LuCaP 35, and LuCaP 23.1 CaP cells were injected directly into tibia of SCID mice. Immunohistochemistry and bone histomorphometrical analyses were performed to characterize these osseous-CaP models. RESULTS: LuCaP 23.1 yields an osteoblastic response, LNCaP yields mixed lesions, and LuCaP 35 and PC-3 result in osteolytic responses. We have detected osteoprotegerin, RANK ligand, parathyroid hormone-related protein, and endothelin-1, proteins associated with bone growth and remodeling, in the CaP cells grown in the bone. CONCLUSIONS: These animal models can be used to study biological interactions, pathways, and potential therapeutic targets, and also to evaluate new agents for treatment and prevention of CaP bone metastasis. Copyright 2002 Wiley-Liss, Inc.
BACKGROUND: To improve the therapy of advanced prostate cancer (CaP), it is critical to develop animal models that mimic CaP bone metastases. Unlike the human disease, CaP xenograft models rarely metastasize spontaneously to bone from the orthotopic site of primary tumor growth. METHODS: Single-cell suspensions of LNCaP, PC-3, LuCaP 35, and LuCaP 23.1 CaP cells were injected directly into tibia of SCIDmice. Immunohistochemistry and bone histomorphometrical analyses were performed to characterize these osseous-CaP models. RESULTS: LuCaP 23.1 yields an osteoblastic response, LNCaP yields mixed lesions, and LuCaP 35 and PC-3 result in osteolytic responses. We have detected osteoprotegerin, RANK ligand, parathyroid hormone-related protein, and endothelin-1, proteins associated with bone growth and remodeling, in the CaP cells grown in the bone. CONCLUSIONS: These animal models can be used to study biological interactions, pathways, and potential therapeutic targets, and also to evaluate new agents for treatment and prevention of CaP bone metastasis. Copyright 2002 Wiley-Liss, Inc.
Authors: Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate Journal: J Clin Invest Date: 2010-07-19 Impact factor: 14.808
Authors: Christopher T Winkelmann; Said Daibes Figueroa; Gary L Sieckman; Tammy L Rold; Timothy J Hoffman Journal: Mol Imaging Biol Date: 2012-12 Impact factor: 3.488
Authors: Dali Zheng; Keith F Decker; Tianhua Zhou; Jianquan Chen; Zongtai Qi; Kathryn Jacobs; Katherine N Weilbaecher; Eva Corey; Fanxin Long; Li Jia Journal: Mol Cancer Res Date: 2013-02-05 Impact factor: 5.852
Authors: Jami Mandelin; Marina Cardó-Vila; Wouter H P Driessen; Paul Mathew; Nora M Navone; Sue-Hwa Lin; Christopher J Logothetis; Anna Cecilia Rietz; Andrey S Dobroff; Bettina Proneth; Richard L Sidman; Renata Pasqualini; Wadih Arap Journal: Proc Natl Acad Sci U S A Date: 2015-03-11 Impact factor: 11.205
Authors: Murali Ravoori; Aneta J Czaplinska; Charles Sikes; Lin Han; Evan M Johnson; Wei Qiao; Chaan Ng; Dianna D Cody; William A Murphy; Kim-Anh Do; Nora M Navone; Vikas Kundra Journal: PLoS One Date: 2010-03-29 Impact factor: 3.240